Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Natural Killer Cells and Bortezomib to Treat Cancer [Phase 1]
This Phase 1 clinical trial update reports on the combination of natural killer cells and bortezomib for several cancers, and the study has …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Universal CAR-T Cells Targeting Multiple Myeloma [Phase 1]
Phase 1 clinical trial update for universal CAR-T cells targeting multiple myeloma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating frontline T-cell engager versus autologous stem cell transplant with MRD-guided sequential intensification…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma [Phase 1]
Phase 1 trial update for allogeneic P-BCMA-ALLO1 CAR-T cells in multiple myeloma; the study is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Engineered Dendritic Cell Vaccines for Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating an engineered dendritic cell vaccine for multiple myeloma; the study is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer [Phase 2]
Phase 2 clinical trial evaluating autologous T cells engineered to express T-cell receptors against neoantigens in metastatic cancer, curren…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant [Phase 2]
A Phase 2 clinical trial evaluating melphalan with or without siltuximab for multiple myeloma patients undergoing autologous stem cell trans…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: 18F-Fluciclovine PET/CT in Multiple Myeloma [Phase 2]
A Phase 2 clinical trial is evaluating 18F-fluciclovine PET/CT imaging in patients with multiple myeloma, including newly diagnosed and rela…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a frontline combination CAR-T cell therapy for multiple myeloma or plasmacytoma is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 study evaluating a novel gene therapy in patients with relapsed and refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma [Phase 1, Phase 2]
A National Cancer Institute trial is evaluating the combination of mirdametinib and sirolimus in relapsed/refractory, RAS-mutated multiple m…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Tissue Collection for Studies of Lymph Cancer
Clinical trial update describing tissue collection for studies of lymph cancers; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event [NA]
ClinicalTrials.gov update describes a study on continuous temperature monitoring to detect cytokine release syndrome during immunotherapy, w…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma [NA]
This clinical trial update notes that a study evaluating 'pseudo-scanner' MRI sequences to detect bone lesions in multiple myeloma is curren…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer [NA]
This clinical trial update notes an ongoing study at MD Anderson Cancer Center evaluating a decision aid website to help cancer patients mak…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma [Phase 2]
A Phase 2 study evaluating three dosing schedules of daratumumab in participants with smoldering multiple myeloma has completed and posted r…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 dose-escalation trial of teclistamab (Tecvayli), a humanized BCMA-CD3 bispecific antibody, in relapsed or refractory multiple myelom…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 3]
This clinical trial update describes a Phase 3 study comparing Linvoseltamab as monotherapy or in combination with Carfilzomib versus standa…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
This clinical trial update describes a study using integrative multi-omics analysis to predict the clinical evolution of monoclonal gammopat…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) [Phase 3]
A Phase 3 clinical trial (MagnetisMM-32) evaluating Elranatamab for relapsed or refractory multiple myeloma, including patients previously t…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant [Phase 3]
Phase 3 trial evaluating elranatamab with daratumumab and lenalidomide versus daratumumab, bortezomib, lenalidomide, and dexamethasone in ne…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma [NA]
This clinical trial evaluates a six-month, individualized, hybrid, real-life adapted physical activity program for improving quality of life…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Pilot Imaging Study of Leukemia [Phase 1]
Phase 1 pilot imaging study in leukemia is currently recruiting. Conditions listed include acute lymphoblastic leukemia, acute myeloid leuke…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) [Phase 1]
Phase 1 study MagnetisMM-30 is evaluating the combination of elranatamab and iberdomide in relapsed or refractory multiple myeloma; the tria…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating the combination of inobrodib, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma i…